At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNRX Quoin Pharmaceuticals
Trading 05-20 12:44:03 EDT
0.7501
-0.0101
-1.33%
High0.7650
Low0.7347
Vol28.59K
Open0.7600
D1 Closing0.7602
Amplitude3.99%
Mkt Cap2.99M
Tradable Cap2.97M
Total Shares3.98M
T/O21.35K
T/O Rate0.72%
Tradable Shares3.96M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Quoin Pharmaceuticals on the Brink: Nasdaq Deficiency Notice Threatens Stability and Investor Confidence
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.